A detailed history of Charles Schwab Investment Management Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 1,626,347 shares of VRTX stock, worth $659 Million. This represents 0.15% of its overall portfolio holdings.

Number of Shares
1,626,347
Previous 1,605,986 1.27%
Holding current value
$659 Million
Previous $753 Million 0.48%
% of portfolio
0.15%
Previous 0.15%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$460.0 - $505.78 $9.37 Million - $10.3 Million
20,361 Added 1.27%
1,626,347 $756 Million
Q2 2024

Aug 12, 2024

BUY
$392.81 - $485.53 $19.4 Million - $24 Million
49,374 Added 3.17%
1,605,986 $753 Million
Q1 2024

May 08, 2024

BUY
$407.69 - $446.08 $19.3 Million - $21.1 Million
47,406 Added 3.14%
1,556,612 $651 Million
Q4 2023

Feb 06, 2024

BUY
$343.0 - $410.68 $14.3 Million - $17.2 Million
41,778 Added 2.85%
1,509,206 $614 Million
Q3 2023

Nov 08, 2023

BUY
$338.18 - $362.46 $5.94 Million - $6.37 Million
17,564 Added 1.21%
1,467,428 $510 Million
Q2 2023

Aug 09, 2023

BUY
$314.42 - $351.91 $2.12 Million - $2.37 Million
6,727 Added 0.47%
1,449,864 $510 Million
Q1 2023

May 11, 2023

BUY
$283.23 - $323.1 $7.68 Million - $8.76 Million
27,109 Added 1.91%
1,443,137 $455 Million
Q4 2022

Feb 13, 2023

BUY
$285.76 - $321.48 $8.03 Million - $9.03 Million
28,088 Added 2.02%
1,416,028 $409 Million
Q3 2022

Nov 14, 2022

BUY
$273.83 - $305.53 $6.53 Million - $7.29 Million
23,848 Added 1.75%
1,387,940 $402 Million
Q2 2022

Aug 15, 2022

BUY
$234.96 - $292.55 $8.61 Million - $10.7 Million
36,626 Added 2.76%
1,364,092 $384 Million
Q1 2022

May 13, 2022

BUY
$221.42 - $260.97 $14.6 Million - $17.2 Million
65,778 Added 5.21%
1,327,466 $346 Million
Q4 2021

Feb 11, 2022

BUY
$177.01 - $223.45 $3.49 Million - $4.4 Million
19,703 Added 1.59%
1,261,688 $277 Million
Q3 2021

Nov 16, 2021

BUY
$181.39 - $202.99 $4.63 Million - $5.19 Million
25,546 Added 2.1%
1,241,985 $225 Million
Q2 2021

Aug 16, 2021

BUY
$187.49 - $221.1 $1.88 Million - $2.21 Million
10,014 Added 0.83%
1,216,439 $245 Million
Q1 2021

May 17, 2021

SELL
$207.02 - $241.31 $11.2 Million - $13.1 Million
-54,152 Reduced 4.3%
1,206,425 $259 Million
Q4 2020

Feb 16, 2021

SELL
$207.01 - $276.09 $7.05 Million - $9.4 Million
-34,061 Reduced 2.63%
1,260,577 $298 Million
Q3 2020

Nov 13, 2020

BUY
$255.65 - $303.1 $15 Million - $17.8 Million
58,738 Added 4.75%
1,294,638 $352 Million
Q2 2020

Aug 14, 2020

BUY
$225.48 - $295.8 $15.9 Million - $20.8 Million
70,386 Added 6.04%
1,235,900 $359 Million
Q1 2020

May 15, 2020

BUY
$199.77 - $247.81 $7.38 Million - $9.15 Million
36,925 Added 3.27%
1,165,514 $277 Million
Q4 2019

Feb 07, 2020

BUY
$166.71 - $223.91 $3.26 Million - $4.38 Million
19,563 Added 1.76%
1,128,589 $247 Million
Q3 2019

Nov 08, 2019

BUY
$166.23 - $187.09 $6.45 Million - $7.26 Million
38,797 Added 3.63%
1,109,026 $188 Million
Q2 2019

Aug 09, 2019

BUY
$164.61 - $190.37 $2.05 Million - $2.37 Million
12,447 Added 1.18%
1,070,229 $196 Million
Q1 2019

May 14, 2019

BUY
$163.73 - $194.7 $12.9 Million - $15.4 Million
78,875 Added 8.06%
1,057,782 $195 Million
Q4 2018

Feb 14, 2019

BUY
$151.91 - $192.21 $7.06 Million - $8.94 Million
46,494 Added 4.99%
978,907 $162 Million
Q3 2018

Nov 13, 2018

BUY
$167.73 - $192.74 $4.23 Million - $4.86 Million
25,205 Added 2.78%
932,413 $180 Million
Q2 2018

Aug 08, 2018

SELL
$145.72 - $169.96 $9.29 Million - $10.8 Million
-63,727 Reduced 6.56%
907,208 $154 Million
Q1 2018

May 07, 2018

BUY
$151.6 - $177.13 $3 Million - $3.5 Million
19,759 Added 2.08%
970,935 $158 Million
Q4 2017

Jan 17, 2018

BUY
$137.28 - $155.55 $3.58 Million - $4.06 Million
26,101 Added 2.82%
951,176 $143 Million
Q3 2017

Nov 13, 2017

BUY
$148.13 - $162.24 $137 Million - $150 Million
925,075
925,075 $141 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $104B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.